Generalized Pustular Psoriasis Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | AbbVie, Janssen, Novartis, Kyowa Hakko Kirin, Boehringer Ingelheim, Eisai, Eli Lilly, AnaptysBio, Mitsubishi Tanabe Pharma

As per DelveInsight, the Generalized Pustular Psoriasis Market is anticipated to evolve immensely in the coming years owing to the increase in the prevalence of GPP in the 7MM, the potential launch of pipeline therapies, and increasing research and development activities by pharmaceutical companies in the therapeutics domain.

DelveInsight's "Generalized Pustular Psoriasis (GPP) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Generalized Pustular Psoriasis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Generalized Pustular Psoriasis therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Generalized Pustular Psoriasis treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Generalized Pustular Psoriasis: An Overview
Generalized Pustular Psoriasis (GPP) is a subtype of pustular psoriasis characterized by sudden, repeated episodes of high-grade fever, generalized erythematous pustular rashes, painful and occasionally disfiguring cutaneous manifestations with sepsis-like.

Psoriasis is an immune-mediated disease that is clinically classified into two groups: pustular and non-pustular lesions. Non-pustular psoriasis is further subdivided into Psoriasis vulgaris (early and late onset), Guttate psoriasis, Erythrodermic psoriasis, Palmoplantar psoriasis, Psoriatic arthritis (PsA), and Inverse psoriasis. The Pustular variant of psoriasis is further subdivided into generalized and localized forms.

Generalized Pustular Psoriasis is a rare, severe, and potentially life-threatening variant of psoriasis that has been associated with abnormalities in the cytokine (messenger protein) interleukin-36 receptor-antagonist signaling. This is due to recessive IL36RN gene mutations systemic symptoms and systemic upset. Generalized Pustular Psoriasis and other forms of psoriasis are caused by abnormal inflammation, which, if it goes uncontrolled, can damage the body's tissues and organs.

Currently, there are no approved therapies for Generalized Pustular Psoriasis in the United States or Europe. Typically diagnosed after age 30, these patients can die from complications of bacteremia, sepsis, acute respiratory distress syndrome, and cardiac failure. Most patients are treated off-label with systemic anti-inflammatory agents, including high-dose cyclosporine, methotrexate, corticosteroids, retinoids, or biologics, which are often tapered or discontinued due to lack of efficacy or toxicity.

Generalized Pustular Psoriasis Market Key Facts
• As per a study by Mirza et al. (2021), The annual prevalence of Generalized Pustular Psoriasis in the French population has been estimated at 1.76 per million. The prevalence in Japan has been estimated at 7.46 per million.
• According to Gordan et al. (2022), the prevalence of Generalized Pustular Psoriasis is between 0.004% to 0.046% and this condition has a mortality range of 2% to 16%. Gordon also said that it may affect as many as 12% of those who have plaque psoriasis, and moreover, 70% of patients who have Generalized Pustular Psoriasis also have plaque psoriasis.
• As per a study by Labwohl et al. (2022), Generalized Pustular Psoriasis is a rare disease, with a reported prevalence of between 0.01 and 0.02/10,000 in France to 5/10,000 in Germany.
• In a study by Twelves et al. (2019), about half of Generalized Pustular Psoriasis cases were concomitant with psoriasis vulgaris. Generalized Pustular Psoriasis is more frequent in women than in men, with male-to-female ratios of 0.5-0.9. Generalized Pustular Psoriasis seems to occur in all ages, and the mean age at onset has been found to be between 40 and 50 years.

Generalized Pustular Psoriasis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Generalized Pustular Psoriasis therapies in the market. It also provides a detailed assessment of the Generalized Pustular Psoriasis market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Generalized Pustular Psoriasis drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Generalized Pustular Psoriasis Market Will Grow by 2032:
https://www.delveinsight.com/report-store/generalized-pustular-psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Generalized Pustular Psoriasis Epidemiology
The epidemiology section covers detailed insights into the historical, and current Generalized Pustular Psoriasis patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Generalized Pustular Psoriasis Epidemiology Segmented as -
• Age-specific Diagnosed Prevalent Population of GPP in the 7MM (2019-2032)
• Total Prevalent Population of GPP in the 7MM (2019-2032)
• Gender-specific Diagnosed Prevalence of GPP in the 7MM (2019-2032)
• Severity-specific Diagnosed Prevalence of GPP in the 7MM (2019-2032)

Get Key Insights Into the Evolving Generalized Pustular Psoriasis Epidemiology Trends @
https://www.delveinsight.com/report-store/generalized-pustular-psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Generalized Pustular Psoriasis Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Generalized Pustular Psoriasis market or expected to be launched during the study period. The analysis covers the market share by Generalized Pustular Psoriasis drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Generalized Pustular Psoriasis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/generalized-pustular-psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Generalized Pustular Psoriasis Therapeutics Assessment
The current therapeutic landscape of Generalized Pustular Psoriasis in the United States is driven by supportive therapies (topical therapies, systemic therapies, biologics, and phototherapy). In EU4 and the UK, for Generalized Pustular Psoriasis, the market is the same as that of the US, with prescriptions for supportive therapies, due to the lack of approved treatment regimens. In the United States, in September 2022, SPEVIGO (spesolimab) was approved in the USA for the treatment of generalized pustular psoriasis (GPP) flares in adults.

Unlike other 7MM countries, Japan is the only one that has a significant number of therapies approved for the treatment of Generalized Pustular Psoriasis. Therefore, the current therapeutic landscape of Generalized Pustular Psoriasis is attributed to both supportive treatment regimens, and approved therapies. However, the treatment can be categorized, as in other countries: topical therapies, phototherapy, oral systemic therapies, and Biologics. Some of the approved drugs for Generalized Pustular Psoriasis in Japan include TREMFYA (Janssen Pharmaceutical); SKYRIZI (AbbVie/Boehringer Ingelheim); HUMIRA (AbbVie/Eisai); LUMICEF (Kyowa Hakko Kirin); COSENTYX (Novartis); REMICADE (Mitsubishi Tanabe Pharma); and ixekizumab (Eli Lilly)

The dynamics of the Generalized Pustular Psoriasis market are anticipated to change in the coming years owing to the rise in healthcare spending across the world, the launch of novel therapies, and the rising cases of Generalized Pustular Psoriasis.

Leading Companies in the Generalized Pustular Psoriasis Therapeutics Market Include
• AbbVie
• Janssen Pharmaceuticals
• Novartis
• Kyowa Hakko Kirin
• Boehringer Ingelheim
• Eisai
• Eli Lilly & Company
• Mitsubishi Tanabe Pharma
• AnaptysBio
And Many Others

Emerging and Marketed Generalized Pustular Psoriasis Therapies Covered in the Report Include
• Tremfya: Janssen Pharmaceuticals
• COSENTYX: Novartis
• Lumicef: Kyowa Hakko Kirin
• Skyrizi: AbbVie/Boehringer Ingelheim
• Humira: AbbVie/Eisai
• Taltz: Eli Lilly & Company
• Remicade: Mitsubishi Tanabe Pharma
• Spesolimab: Boehringer Ingelheim
• ANB019: AnaptysBio
And Many More

Learn More About the Emerging Therapies and key Companies in the Generalized Pustular Psoriasis Therapeutics Market:
https://www.delveinsight.com/sample-request/generalized-pustular-psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Generalized Pustular Psoriasis Competitive Intelligence Analysis
4. Generalized Pustular Psoriasis Market Overview at a Glance
5. Generalized Pustular Psoriasis Background and Overview
6. Generalized Pustular Psoriasis Patient Journey
7. Generalized Pustular Psoriasis Epidemiology and Patient Population
8. Generalized Pustular Psoriasis Treatment Algorithm, Current Treatment, and Medical Practices
9. Generalized Pustular Psoriasis Unmet Needs
10. Key Endpoints of Generalized Pustular Psoriasis Treatment
11. Generalized Pustular Psoriasis Marketed Products
12. Generalized Pustular Psoriasis Emerging Therapies
13. Generalized Pustular Psoriasis Seven Major Market Analysis
14. Attribute Analysis
15. Generalized Pustular Psoriasis Market Outlook (7 major markets)
16. Generalized Pustular Psoriasis Access and Reimbursement Overview
17. KOL Views on the Generalized Pustular Psoriasis Market.
18. Generalized Pustular Psoriasis Market Drivers
19. Generalized Pustular Psoriasis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/generalized-pustular-psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.